Description: Each Pen of CinnoPar® containing 600µg (250 µg /1ml) Teriparatide for subcutaneous injection, produced under EU GMP license.

INN: Teriparatide

Indication: Glucocorticoid-induced osteoporosis, osteoporosis in men and osteoporosis in postmenopausal women who are at high risk for fractures.

Protein type: Hormone

Mechanism of action: Stimulates the bone formation by direct effects on bone-forming cells (osteoblasts), increasing intestinal absorption of calcium and excretion of phosphate.

CinnoPar leaflet (PDF)



Description: Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system.

INN: Adalimumab

Indication: For treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, juvenile idiopathic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, pediatric crohn’s disease, Uveitis.

Protein type: Monoclonal antibody (mAb)

  • Mechanism of action: Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

CinnoRA leaflet (PDF)



Description: This medicine is produced as prefilled syringes containing solution form with two different dosages: 25 mg and 50 mg

INN: Etanercept

Indication: Rheumatoid Arthritis, Plaque Psoriasis, Psoriasis Arthritis, Spondyloarthritis, Ankylosing Spondylitis and Juvenile Idiopathic.

Protein type: Fusion proteins

Mechanism of action: Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF.

Altebrel leaflet (PDF)

Contact Us

English   |   汉语


© Singapore Biotechnology, Pte. Ltd. All rights reserved.